Selective activation of intracellular signalling pathways in dendritic cells for cancer immunotherapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 1, 2012, Pages 29-39

  Arce, Frederick ^a   Kochan, Grazyna ^b   Breckpot, Karine ^c   Stephenson, Holly ^d   Escors, David ^a  

^a Windeyer Institute of Medical Sciences   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; Cytokine; Dendritic cells; Immunotherapy; Lentivector; Signalling; Tlr; Tolerance; Tumor

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; PATTERN RECOGNITION RECEPTOR; SUNITINIB; TOLL LIKE RECEPTOR;

ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL GROWTH; CELL MATURATION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE VECTOR; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; INTERFERON PRODUCTION; INTRACELLULAR SIGNALING; NONHUMAN; PHYLOGENY; SIGNAL TRANSDUCTION; TUMOR IMMUNITY;

EID: 84855286306     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012798764679     Document Type: Article

References (164)

1. Ehrlich, P., Ueber den jetzigen Stand der Karzinom-forschung. Ned. Tijdschr. Geneesk, 1909, 5, 273-290.
2. Burnet, F.M., The concept of immunological surveillance. Progress in experimental tumor research. Fortschritte der experimentellen Tumorforschung, 1970, 13, 1-27.
3. Van den Eynde, B.J.; van der Bruggen, P., T cell defined tumor antigens. Current opinion in immunology, 1997, 9, (5), 684-693.
4. Pittet, M.J.; Mempel, T.R., Regulation of T-cell migration and effector functions: insights from in vivo imaging studies. Immunol Rev, 2008, 221, 107-129.
5. Boon, T.; van der Bruggen, P., Human tumor antigens recognized by T lymphocytes. J Exp Med, 1996, 183, (3), 725-729.
6. Walker, L.S.; Abbas, A.K., The enemy within: keeping selfreactive T cells at bay in the periphery. Nature reviews, 2002, 2, (1), 11-19.
7. Breckpot, K.; Escors, D., Dendritic Cells for Active Anti-cancer Immunotherapy: Targeting Activation Pathways Through Genetic Modification. Endocrine, metabolic & immune disorders drug targets, 2009, 9, 328-343.
8. Wang, L.; Pino-Lagos, K.; de Vries, V.C.; Guleria, I.; Sayegh, M.H.; Noelle, R.J., Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A, 2008, 105, (27), 9331-9336.
9. Latchman, Y.; Wood, C.R.; Chernova, T.; Chaudhary, D.; Borde, M.; Chernova, I.; Iwai, Y.; Long, A.J.; Brown, J.A.; Nunes, R.; Greenfield, E.A.; Bourque, K.; Boussiotis, V.A.; Carter, L.L.; Carreno, B.M.; Malenkovich, N.; Nishimura, H.; Okazaki, T.; Honjo, T.; Sharpe, A.H.; Freeman, G.J., PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol, 2001, 2, (3), 261-268.
10. Belladonna, M.L.; Orabona, C.; Grohmann, U.; Puccetti, P., TGFbeta and kynurenines as the key to infectious tolerance. Trends in molecular medicine, 2009, 15, (2), 41-49.
11. Mahnke, K.; Qian, Y.; Knop, J.; Enk, A.H., Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood, 2003, 101, (12), 4862-4869.
12. Dhodapkar, M.V.; Steinman, R.M., Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. Blood, 2002, 100, (1), 174-177.
13. Dhodapkar, M.V.; Steinman, R.M.; Krasovsky, J.; Munz, C.; Bhardwaj, N., Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med, 2001, 193, (2), 233-238.
14. Zitvogel, L.; Tesniere, A.; Kroemer, G., Cancer despite immunosurveillance: immunoselection and immunosubversion. Nature reviews, 2006, 6, (10), 715-727.
15. Emens, L.A., A new twist on autologous cancer vaccines. Cancer biology & therapy, 2003, 2, (2), 161-163.
16. Lizee, G.; Radvanyi, L.G.; Overwijk, W.W.; Hwu, P., Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res, 2006, 12, (16), 4794-4803.
17. Srivastava, M.K.; Sinha, P.; Clements, V.K.; Rodriguez, P.; Ostrand-Rosenberg, S., Myeloid-derived suppressor cells inhibit Tcell activation by depleting cystine and cysteine. Cancer Res, 2010, 70, (1), 68-77.
18. Biswas, S.K.; Gangi, L.; Paul, S.; Schioppa, T.; Saccani, A.; Sironi, M.; Bottazzi, B.; Doni, A.; Vincenzo, B.; Pasqualini, F.; Vago, L.; Nebuloni, M.; Mantovani, A.; Sica, A., A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood, 2006, 107, (5), 2112-2122.
19. Li, H.; Han, Y.; Guo, Q.; Zhang, M.; Cao, X., Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol, 2009, 182, (1), 240-249.
20. Zhou, G.; Drake, C.G.; Levitsky, H.I., Amplification of tumorspecific regulatory T cells following therapeutic cancer vaccines. Blood, 2006, 107, (2), 628-636.
21. Breckpot, K.; Escors, D.; Arce, F.; Lopes, L.; Karwacz, K.; Van Lint, S.; Keyaerts, M.; Collins, M., HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. J. Virol., 2010, 84, 5627-5636.
22. van Duin, D.; Medzhitov, R.; Shaw, A.C., Triggering TLR signaling in vaccination. Trends Immunol, 2006, 27, (1), 49-55.
23. Iwasaki, A.; Medzhitov, R., Toll-like receptor control of the adaptive immune responses. Nat Immunol, 2004, 5, (10), 987-995.
24. Pasare, C.; Medzhitov, R., Toll-dependent control mechanisms of CD4 T cell activation. Immunity, 2004, 21, (5), 733-741.
25. Pasare, C.; Medzhitov, R., Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol, 2005, 560, 11-18.
26. Rakoff-Nahoum, S.; Medzhitov, R., Toll-like receptors and cancer. Nat Rev Cancer, 2009, 9, (1), 57-63.
27. Yang, Y.; Huang, C.T.; Huang, X.; Pardoll, D.M., Persistent Tolllike receptor signals are required for reversal of regulatory T cellmediated CD8 tolerance. Nat Immunol, 2004, 5, (5), 508-515.
28. Caparros, E.; Munoz, P.; Sierra-Filardi, E.; Serrano-Gomez, D.; Puig-Kroger, A.; Rodriguez-Fernandez, J.L.; Mellado, M.; Sancho, J.; Zubiaur, M.; Corbi, A.L., DC-SIGN ligation on dendritic cells results in ERK and PI3K activation and modulates cytokine production. Blood, 2006, 107, (10), 3950-3958.
29. Luft, T.; Rodionova, E.; Maraskovsky, E.; Kirsch, M.; Hess, M.; Buchholtz, C.; Goerner, M.; Schnurr, M.; Skoda, R.; Ho, A.D., Adaptive functional differentiation of dendritic cells: integrating the network of extra- and intracellular signals. Blood, 2006, 107, (12), 4763-4769.
30. Beutler, B.A., TLRs and innate immunity. Blood, 2009, 113, (7), 1399-1407.
31. Yamamoto, M.; Sato, S.; Hemmi, H.; Hoshino, K.; Kaisho, T.; Sanjo, H.; Takeuchi, O.; Sugiyama, M.; Okabe, M.; Takeda, K.; Akira, S., Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science, 2003, 301, (5633), 640-643.
32. Kawai, T.; Akira, S., Toll-like receptor and RIG-I-like receptor signaling. Annals of the New York Academy of Sciences, 2008, 1143, 1-20.
33. Ardeshna, K.M.; Pizzey, A.R.; Devereux, S.; Khwaja, A., The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood, 2000, 96, (3), 1039-1046.
34. Boulton, T.G.; Nye, S.H.; Robbins, D.J.; Ip, N.Y.; Radziejewska, E.; Morgenbesser, S.D.; DePinho, R.A.; Panayotatos, N.; Cobb, M.H.; Yancopoulos, G.D., ERKs: a family of proteinserine/ threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell, 1991, 65, (4), 663-675.
35. Derijard, B.; Hibi, M.; Wu, I.H.; Barrett, T.; Su, B.; Deng, T.; Karin, M.; Davis, R.J., JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell, 1994, 76, (6), 1025-1037.
36. Kyriakis, J.M.; Banerjee, P.; Nikolakaki, E.; Dai, T.; Rubie, E.A.; Ahmad, M.F.; Avruch, J.; Woodgett, J.R., The stress-activated protein kinase subfamily of c-Jun kinases. Nature, 1994, 369, (6476), 156-160.
37. Lee, J.C.; Laydon, J.T.; McDonnell, P.C.; Gallagher, T.F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M.J.; Heys, J.R.; Landvatter S.W.; et al., A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature, 1994, 372, (6508), 739-746.
38. Han, J.; Lee, J.D.; Bibbs, L.; Ulevitch, R.J., A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science, 1994, 265, (5173), 808-811.
39. Zhang, J.; Yang, P.L.; Gray, N.S., Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer, 2009, 9, (1), 28-39.
40. Hacker, H.; Redecke, V.; Blagoev, B.; Kratchmarova, I.; Hsu, L.C.; Wang, G.G.; Kamps, M.P.; Raz, E.; Wagner, H.; Hacker, G.; Mann, M.; Karin, M., Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature, 2006, 439, (7073), 204-207.
41. Sato, S.; Sanjo, H.; Takeda, K.; Ninomiya-Tsuji, J.; Yamamoto, M.; Kawai, T.; Matsumoto, K.; Takeuchi, O.; Akira, S., Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol, 2005, 6, (11), 1087-1095.
42. Banerjee, A.; Gugasyan, R.; McMahon, M.; Gerondakis, S., Diverse Toll-like receptors utilize Tpl2 to activate extracellular signal-regulated kinase (ERK) in hemopoietic cells. Proc Natl Acad Sci U S A, 2006, 103, (9), 3274-3279.
43. Eliopoulos, A.G.; Dumitru, C.D.; Wang, C.C.; Cho, J.; Tsichlis, P.N., Induction of COX-2 by LPS in macrophages is regulated by Tpl2-dependent CREB activation signals. Embo J, 2002, 21, (18), 4831-4840.
44. Dumitru, C.D.; Ceci, J.D.; Tsatsanis, C.; Kontoyiannis, D.; Stamatakis, K.; Lin, J.H.; Patriotis, C.; Jenkins, N.A.; Copeland, N.G.; Kollias, G.; Tsichlis, P.N., TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell, 2000, 103, (7), 1071-1083.
45. Escors, D.; Lopes, L.; Lin, R.; Hiscott, J.; Akira, S.; Davis, R.J.; Collins, M.K., Targeting dendritic cell signalling to regulate the response to immunisation. Blood, 2008, 111, (6), 3050-3061.
46. Pearson, G.; Robinson, F.; Beers Gibson, T.; Xu, B.E.; Karandikar, M.; Berman, K.; Cobb, M.H., Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocrine reviews, 2001, 22, (2), 153-183.
47. Roberts, P.J.; Der, C.J., Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene, 2007, 26, (22), 3291-3310.
48. Wang, C.; Deng, L.; Hong, M.; Akkaraju, G.R.; Inoue, J.; Chen, Z.J., TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature, 2001, 412, (6844), 346-351.
49. Rescigno, M.; Martino, M.; Sutherland, C.L.; Gold, M.R.; Ricciardi-Castagnoli, P., Dendritic cell survival and maturation are regulated by different signaling pathways. J Exp Med, 1998, 188, (11), 2175-2180.
50. Agrawal, A.; Dillon, S.; Denning, T.L.; Pulendran, B., ERK1-/-mice exhibit Th1 cell polarization and increased susceptibility to experimental autoimmune encephalomyelitis. J Immunol, 2006, 176, (10), 5788-5796.
51. Saraiva, M.; O'Garra, A., The regulation of IL-10 production by immune cells. Nature reviews, 2010, 10, (3), 170-181.
52. Arce, F.; Breckpot, K.; Stephenson, H.; Karwacz, K.; Ehrenstein, M.R.; Collins, M.; Escors, D., Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigenspecific regulatory T cells, and suppresses experimental inflammatory arthritis. Arthritis and rheumatism, 2011, 63, 84-95.
53. Re, F.; Strominger, J.L., Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem, 2001, 276, (40), 37692-37699.
54. Re, F.; Strominger, J.L., IL-10 released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TLR4 or TLR3 in human dendritic cells. J Immunol, 2004, 173, (12), 7548-7555.
55. Slack, E.C.; Robinson, M.J.; Hernanz-Falcon, P.; Brown, G.D.; Williams, D.L.; Schweighoffer, E.; Tybulewicz, V.L.; Reis e Sousa, C., Syk-dependent ERK activation regulates IL-2 and IL-10 production by DC stimulated with zymosan. Eur J Immunol, 2007, 37, (6), 1600-1612.
56. Qian, C.; Jiang, X.; An, H.; Yu, Y.; Guo, Z.; Liu, S.; Xu, H.; Cao, X., TLR agonists promote ERK-mediated preferential IL-10 production of regulatory dendritic cells (diffDCs), leading to NK-cell activation. Blood, 2006, 108, (7), 2307-2315.
57. Manicassamy, S.; Ravindran, R.; Deng, J.; Oluoch, H.; Denning, T.L.; Kasturi, S.P.; Rosenthal, K.M.; Evavold, B.D.; Pulendran, B., Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity. Nat Med, 2009, 15, (4), 401-409.
58. Ninomiya-Tsuji, J.; Kishimoto, K.; Hiyama, A.; Inoue, J.; Cao, Z.; Matsumoto, K., The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature, 1999, 398, (6724), 252-256.
59. Moriguchi, T.; Kuroyanagi, N.; Yamaguchi, K.; Gotoh, Y.; Irie, K.; Kano, T.; Shirakabe, K.; Muro, Y.; Shibuya, H.; Matsumoto, K.; Nishida, E.; Hagiwara, M., A novel kinase cascade mediated by mitogen-activated protein kinase kinase 6 and MKK3. J Biol Chem, 1996, 271, (23), 13675-13679.
60. Hammaker, D.R.; Boyle, D.L.; Inoue, T.; Firestein, G.S., Regulation of the JNK pathway by TGF-beta activated kinase 1 in rheumatoid arthritis synoviocytes. Arthritis research & therapy, 2007, 9, (3), R57.
61. Arrighi, J.F.; Rebsamen, M.; Rousset, F.; Kindler, V.; Hauser, C., A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. J Immunol, 2001, 166, (6), 3837-3845.
62. Yu, Q.; Kovacs, C.; Yue, F.Y.; Ostrowski, M.A., The role of the p38 mitogen-activated protein kinase, extracellular signal-regulated kinase, and phosphoinositide-3-OH kinase signal transduction pathways in CD40 ligand-induced dendritic cell activation and expansion of virus-specific CD8+ T cell memory responses. J Immunol, 2004, 172, (10), 6047-6056.
63. Lu, H.T.; Yang, D.D.; Wysk, M.; Gatti, E.; Mellman, I.; Davis, R.J.; Flavell, R.A., Defective IL-12 production in mitogenactivated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice. Embo J, 1999, 18, (7), 1845-1857.
64. Gupta, S.; Barrett, T.; Whitmarsh, A.J.; Cavanagh, J.; Sluss, H.K.; Derijard, B.; Davis, R.J., Selective interaction of JNK protein kinase isoforms with transcription factors. Embo J, 1996, 15, (11), 2760-2770.
65. Junttila, M.R.; Li, S.P.; Westermarck, J., Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. Faseb J, 2008, 22, (4), 954-965.
66. Morton, S.; Davis, R.J.; Cohen, P., Signalling pathways involved in multisite phosphorylation of the transcription factor ATF-2. FEBS Lett, 2004, 572, (1-3), 177-183.
67. Morton, S.; Davis, R.J.; McLaren, A.; Cohen, P., A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun. Embo J, 2003, 22, (15), 3876-3886.
68. Nakahara, T.; Uchi, H.; Urabe, K.; Chen, Q.; Furue, M.; Moroi, Y., Role of c-Jun N-terminal kinase on lipopolysaccharide induced maturation of human monocyte-derived dendritic cells. Int Immunol, 2004, 16, (12), 1701-1709.
69. Sen, R.; Baltimore, D., Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell, 1986, 47, (6), 921-928.
70. Ghosh, S.; Karin, M., Missing pieces in the NF-kappaB puzzle. Cell, 2002, 109 Suppl, S81-96.
71. Rothwarf, D.M.; Karin, M., The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE, 1999, 1999, (5), RE1.
72. Edwards, M.R.; Bartlett, N.W.; Clarke, D.; Birrell, M.; Belvisi, M.; Johnston, S.L., Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease. Pharmacology & therapeutics, 2009, 121, (1), 1-13.
73. Lee, C.H.; Jeon, Y.T.; Kim, S.H.; Song, Y.S., NF-kappaB as a potential molecular target for cancer therapy. BioFactors (Oxford, England), 2007, 29, (1), 19-35.
74. Akira, S.; Uematsu, S.; Takeuchi, O., Pathogen recognition and innate immunity. Cell, 2006, 124, (4), 783-801.
75. Wang, R.F.; Miyahara, Y.; Wang, H.Y., Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene, 2008, 27, (2), 181-189.
76. Hacker, H.; Karin, M., Regulation and function of IKK and IKKrelated kinases. Sci STKE, 2006, 2006, (357), re13.
77. Dawson, S.; Hastings, R.; Takayanagi, K.; Reynolds, S.; Low, P.; Billett, M.; Mayer, R.J., The 26S-proteasome: regulation and substrate recognition. Molecular biology reports, 1997, 24, (1-2), 39-44.
78. Senftleben, U.; Cao, Y.; Xiao, G.; Greten, F.R.; Krahn, G.; Bonizzi, G.; Chen, Y.; Hu, Y.; Fong, A.; Sun, S.C.; Karin, M., Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science, 2001, 293, (5534), 1495-1499.
79. Lawrence, T.; Bebien, M., IKKalpha in the regulation of inflammation and adaptive immunity. Biochem Soc Trans, 2007, 35, (Pt 2), 270-272.
80. Rowe, H.M.; Lopes, L.; Brown, N.; Efklidou, S.; Smallie, T.; Karrar, S.; Kaye, P.M.; Collins, M.K., Expression of vFLIP in a lentiviral vaccine vector activates NF-{kappa}B, matures dendritic cells, and increases CD8+ T-cell responses. J Virol, 2009, 83, (4), 1555-1562.
81. Andreakos, E.; Williams, R.O.; Wales, J.; Foxwell, B.M.; Feldmann, M., Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant. Proc Natl Acad Sci U S A, 2006, 103, (39), 14459-14464.
82. Breckpot, K.; Aerts-Toegaert, C.; Heirman, C.; Peeters, U.; Beyaert, R.; Aerts, J.L.; Thielemans, K., Attenuated expression of A20 markedly increases the efficacy of double-stranded RNAactivated dendritic cells as an anti-cancer vaccine. J Immunol, 2009, 182, (2), 860-870.
83. Kawai, T.; Akira, S., Signaling to NF-kappaB by Toll-like receptors. Trends in molecular medicine, 2007, 13, (11), 460-469.
84. Coornaert, B.; Carpentier, I.; Beyaert, R., A20: central gatekeeper in inflammation and immunity. J Biol Chem, 2009, 284, (13), 8217-8221.
85. Shi, M.; Deng, W.; Bi, E.; Mao, K.; Ji, Y.; Lin, G.; Wu, X.; Tao, Z.; Li, Z.; Cai, X.; Sun, S.; Xiang, C.; Sun, B., TRIM30 alpha negatively regulates TLR-mediated NF-kappa B activation by targeting TAB2 and TAB3 for degradation. Nat Immunol, 2008, 9, (4), 369-377.
86. Bowie, A.G., TRIM-ing down Tolls. Nat Immunol, 2008, 9, (4), 348-350.
87. Barisic, S.; Strozyk, E.; Peters, N.; Walczak, H.; Kulms, D., Identification of PP2A as a crucial regulator of the NF-kappaB feedback loop: its inhibition by UVB turns NF-kappaB into a pro-apoptotic factor. Cell death and differentiation, 2008, 15, (11), 1681-1690.
88. Zitvogel, L.; Apetoh, L.; Ghiringhelli, F.; Kroemer, G., Immunological aspects of cancer chemotherapy. Nature reviews, 2008, 8, (1), 59-73.
89. Casares, N.; Pequignot, M.O.; Tesniere, A.; Ghiringhelli, F.; Roux, S.; Chaput, N.; Schmitt, E.; Hamai, A.; Hervas-Stubbs, S.; Obeid, M.; Coutant, F.; Metivier, D.; Pichard, E.; Aucouturier, P.; Pierron, G.; Garrido, C.; Zitvogel, L.; Kroemer, G., Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med, 2005, 202, (12), 1691-1701.
90. Apetoh, L.; Ghiringhelli, F.; Tesniere, A.; Obeid, M.; Ortiz, C.; Criollo, A.; Mignot, G.; Maiuri, M.C.; Ullrich, E.; Saulnier, P.; Yang, H.; Amigorena, S.; Ryffel, B.; Barrat, F.J.; Saftig, P.; Levi, F.; Lidereau, R.; Nogues, C.; Mira, J.P.; Chompret, A.; Joulin, V.; Clavel-Chapelon, F.; Bourhis, J.; Andre, F.; Delaloge, S.; Tursz, T.; Kroemer, G.; Zitvogel, L., Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med, 2007, 13, (9), 1050-1059.
91. Ghiringhelli, F.; Apetoh, L.; Tesniere, A.; Aymeric, L.; Ma, Y.; Ortiz, C.; Vermaelen, K.; Panaretakis, T.; Mignot, G.; Ullrich, E.; Perfettini, J.L.; Schlemmer, F.; Tasdemir, E.; Uhl, M.; Genin, P.; Civas, A.; Ryffel, B.; Kanellopoulos, J.; Tschopp, J.; Andre, F.; Lidereau, R.; McLaughlin, N.M.; Haynes, N.M.; Smyth, M.J.; Kroemer, G.; Zitvogel, L., Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med, 2009, 15, (10), 1170-1178.
92. Finke, J.H.; Rini, B.; Ireland, J.; Rayman, P.; Richmond, A.; Golshayan, A.; Wood, L.; Elson, P.; Garcia, J.; Dreicer, R.; Bukowski, R., Sunitinib reverses type-1 immune suppression and decreases Tregulatory cells in renal cell carcinoma patients. Clin Cancer Res, 2008, 14, (20), 6674-6682.
93. Xin, H.; Zhang, C.; Herrmann, A.; Du, Y.; Figlin, R.; Yu, H., Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res, 2009, 69, (6), 2506-2513.
94. Jackson, A.M.; Mulcahy, L.A.; Zhu, X.W.; O'Donnell, D.; Patel, P.M., Tumour-mediated disruption of dendritic cell function: inhibiting the MEK1/2-p44/42 axis restores IL-12 production and Th1- generation. International journal of cancer, 2008, 123, (3), 623-632.
95. Puig-Kroger, A.; Relloso, M.; Fernandez-Capetillo, O.; Zubiaga, A.; Silva, A.; Bernabeu, C.; Corbi, A.L., Extracellular signalregulated protein kinase signaling pathway negatively regulates the phenotypic and functional maturation of monocyte-derived human dendritic cells. Blood, 2001, 98, (7), 2175-2182.
96. Fujita, H.; Asahina, A.; Komine, M.; Tamaki, K., ERK inhibitor PD98059 promotes the phenotypic and functional maturation of murine resident Langerhans cells. The Journal of dermatology, 2007, 34, (6), 403-406.
97. Yanagawa, Y.; Iijima, N.; Iwabuchi, K.; Onoe, K., Activation of extracellular signal-related kinase by TNF-alpha controls the maturation and function of murine dendritic cells. J Leukoc Biol, 2002, 71, (1), 125-132.
98. Fenton, M.S.; Marion, K.M.; Salem, A.K.; Hogen, R.; Naeim, F.; Hershman, J.M., Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer. Thyroid, 20, (9), 965-974.
99. Nishioka, C.; Ikezoe, T.; Yang, J.; Takeshita, A.; Taniguchi, A.; Komatsu, N.; Togitani, K.; Koeffler, H.P.; Yokoyama, A., Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene. Leukemia research, 2008, 32, (6), 865-872.
100. da Silva Correia, J.; Soldau, K.; Christen, U.; Tobias, P.S.; Ulevitch, R.J., Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. transfer from CD14 to TLR4 and MD-2. J Biol Chem, 2001, 276, (24), 21129-21135.
101. Pasare, C.; Medzhitov, R., Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science, 2003, 299, (5609), 1033-1036.
102. Abdel-Wahab, Z.; Cisco, R.; Dannull, J.; Ueno, T.; Abdel-Wahab, O.; Kalady, M.F.; Onaitis, M.W.; Tyler, D.S.; Pruitt, S.K., Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses. The Journal of surgical research, 2005, 124, (2), 264-273.
103. Bonehill, A.; Tuyaerts, S.; Van Nuffel, A.M.; Heirman, C.; Bos, T.J.; Fostier, K.; Neyns, B.; Thielemans, K., Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther, 2008, 16, (6), 1170-1180.
104. Cisco, R.M.; Abdel-Wahab, Z.; Dannull, J.; Nair, S.; Tyler, D.S.; Gilboa, E.; Vieweg, J.; Daaka, Y.; Pruitt, S.K., Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4. J Immunol, 2004, 172, (11), 7162-7168.
105. Xu, Y.; Darcy, P.K.; Kershaw, M.H., Tumor-specific dendritic cells generated by genetic redirection of Toll-like receptor signaling against the tumor-associated antigen, erbB2. Cancer Gene Therapy, 2007, 14, (9), 773-780.
106. Akazawa, T.; Shingai, M.; Sasai, M.; Ebihara, T.; Inoue, N.; Matsumoto, M.; Seya, T., Tumor immunotherapy using bone marrow-derived dendritic cells overexpressing Toll-like receptor adaptors. FEBS Lett, 2007, 581, (18), 3334-3340.
107. Karwacz, K.; Mukherjee, S.; Apolonia, L.; Blundell, M.P.; Bouma, G.; Escors, D.; Collins, M.K.; Thrasher, A.J., Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy. J Virol, 2009, 83, (7), 3094-3103.
108. Raingeaud, J.; Whitmarsh, A.J.; Barrett, T.; Derijard, B.; Davis, R.J., MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol Cell Biol, 1996, 16, (3), 1247-1255.
109. Lei, K.; Nimnual, A.; Zong, W.X.; Kennedy, N.J.; Flavell, R.A.; Thompson, C.B.; Bar-Sagi, D.; Davis, R.J., The Bax subfamily of Bcl2-related proteins is essential for apoptotic signal transduction by c-Jun NH(2)-terminal kinase. Mol Cell Biol, 2002, 22, (13), 4929-4942.
110. Chi, H.; Barry, S.P.; Roth, R.J.; Wu, J.J.; Jones, E.A.; Bennett, A.M.; Flavell, R.A., Dynamic regulation of pro- and antiinflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci U S A, 2006, 103, (7), 2274-2279.
111. Salojin, K.V.; Owusu, I.B.; Millerchip, K.A.; Potter, M.; Platt, K.A.; Oravecz, T., Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J Immunol, 2006, 176, (3), 1899-1907.
112. Zhao, Q.; Wang, X.; Nelin, L.D.; Yao, Y.; Matta, R.; Manson, M.E.; Baliga, R.S.; Meng, X.; Smith, C.V.; Bauer, J.A.; Chang, C.H.; Liu, Y., MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J Exp Med, 2006, 203, (1), 131-140.
113. Saccani, S.; Pantano, S.; Natoli, G., p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat Immunol, 2002, 3, (1), 69-75.
114. Firat, H.; Garcia-Pons, F.; Tourdot, S.; Pascolo, S.; Scardino, A.; Garcia, Z.; Michel, M.L.; Jack, R.W.; Jung, G.; Kosmatopoulos, K.; Mateo, L.; Suhrbier, A.; Lemonnier, F.A.; Langlade-Demoyen, P., H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur J Immunol, 1999, 29, (10), 3112-3121.
115. Dillon, S.; Agrawal, S.; Banerjee, K.; Letterio, J.; Denning, T.L.; Oswald-Richter, K.; Kasprowicz, D.J.; Kellar, K.; Pare, J.; van Dyke, T.; Ziegler, S.; Unutmaz, D.; Pulendran, B., Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigenpresenting cells and immunological tolerance. J Clin Invest, 2006, 116, (4), 916-928.
116. Jing, Z.; Yuan, X.; Zhang, J.; Huang, X.; Zhang, Z.; Liu, J.; Zhang, M.; Oyang, J.; Zhang, Y.; Zhang, Z.; Yang, R., Chromosome 1 Open Reading Frame 190 Promotes Activation of NF-{kappa}B Canonical Pathway and Resistance of Dendritic Cells to Tumor-Associated Inhibition In Vitro. J Immunol, 2010.
117. Field, N.; Low, W.; Daniels, M.; Howell, S.; Daviet, L.; Boshoff, C.; Collins, M., KSHV vFLIP binds to IKK-gamma to activate IKK. J Cell Sci, 2003, 116, (Pt 18), 3721-3728.
118. Bagneris, C.; Ageichik, A.V.; Cronin, N.; Wallace, B.; Collins, M.; Boshoff, C.; Waksman, G.; Barrett, T., Crystal structure of a vFlip- IKKgamma complex: insights into viral activation of the IKK signalosome. Molecular cell, 2008, 30, (5), 620-631.
119. Beyaert, R.; Heyninck, K.; Van Huffel, S., A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis. Biochem Pharmacol, 2000, 60, (8), 1143-1151.
120. Wertz, I.E.; O'Rourke, K.M.; Zhou, H.; Eby, M.; Aravind, L.; Seshagiri, S.; Wu, P.; Wiesmann, C.; Baker, R.; Boone, D.L.; Ma, A.; Koonin, E.V.; Dixit, V.M., De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature, 2004, 430, (7000), 694-699.
121. Boone, D.L.; Turer, E.E.; Lee, E.G.; Ahmad, R.C.; Wheeler, M.T.; Tsui, C.; Hurley, P.; Chien, M.; Chai, S.; Hitotsumatsu, O.; McNally, E.; Pickart, C.; Ma, A., The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol, 2004, 5, (10), 1052-1060.
122. Zhang, S.Q.; Kovalenko, A.; Cantarella, G.; Wallach, D., Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity, 2000, 12, (3), 301-311.
123. Saitoh, T.; Yamamoto, M.; Miyagishi, M.; Taira, K.; Nakanishi, M.; Fujita, T.; Akira, S.; Yamamoto, N.; Yamaoka, S., A20 is a negative regulator of IFN regulatory factor 3 signaling. J Immunol, 2005, 174, (3), 1507-1512.
124. Wang, Y.Y.; Li, L.; Han, K.J.; Zhai, Z.; Shu, H.B., A20 is a potent inhibitor of TLR3- and Sendai virus-induced activation of NFkappaB and ISRE and IFN-beta promoter. FEBS Lett, 2004, 576, (1-2), 86-90.
125. Heyninck, K.; Beyaert, R., The cytokine-inducible zinc finger protein A20 inhibits IL-1-induced NF-kappaB activation at the level of TRAF6. FEBS Lett, 1999, 442, (2-3), 147-150.
126. Song, X.T.; Evel-Kabler, K.; Shen, L.; Rollins, L.; Huang, X.F.; Chen, S.Y., A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat Med, 2008, 14, (3), 258-265.
127. Escors, D.; Breckpot, K., Lentiviral Vectors in Gene Therapy: Their Current Status and Future Potential. Arch Immunol Ther Exp, 2010, 58, (2), 107-119.
128. Bokhoven, M.; Stephen, S.L.; Knight, S.; Gevers, E.F.; Robinson, I.C.; Takeuchi, Y.; Collins, M.K., Insertional gene activation by lentiviral and gammaretroviral vectors. J Virol, 2009, 83, (1), 283-294.
129. Howe, S.J.; Mansour, M.R.; Schwarzwaelder, K.; Bartholomae, C.; Hubank, M.; Kempski, H.; Brugman, M.H.; Pike-Overzet, K.; Chatters, S.J.; de Ridder, D.; Gilmour, K.C.; Adams, S.; Thornhill, S.I.; Parsley, K.L.; Staal, F.J.; Gale, R.E.; Linch, D.C.; Bayford, J.; Brown, L.; Quaye, M.; Kinnon, C.; Ancliff, P.; Webb, D.K.; Schmidt, M.; von Kalle, C.; Gaspar, H.B.; Thrasher, A.J., Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest, 2008, 118, (9), 3143-3150.
130. Knight, S.; Bokhoven, M.; Collins, M.; Takeuchi, Y., Effect of the internal promoter on insertional gene activation by lentiviral vectors with an intact HIV long terminal repeat. J Virol, 2010, 84, (9), 4856-4859.
131. Hacein-Bey-Abina, S.; Von Kalle, C.; Schmidt, M.; McCormack, M.P.; Wulffraat, N.; Leboulch, P.; Lim, A.; Osborne, C.S.; Pawliuk, R.; Morillon, E.; Sorensen, R.; Forster, A.; Fraser, P.; Cohen, J.I.; de Saint Basile, G.; Alexander, I.; Wintergerst, U.; Frebourg, T.; Aurias, A.; Stoppa-Lyonnet, D.; Romana, S.; Radford-Weiss, I.; Gross, F.; Valensi, F.; Delabesse, E.; Macintyre, E.; Sigaux, F.; Soulier, J.; Leiva, L.E.; Wissler, M.; Prinz, C.; Rabbitts, T.H.; Le Deist, F.; Fischer, A.; Cavazzana-Calvo, M., LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 2003, 302, (5644), 415-419.
132. Arce, F.; Rowe, H.M.; Chain, B.; Lopes, L.; Collins, M.K., Lentiviral vectors transduce proliferating dendritic cell precursors leading to persistent antigen presentation and immunization. Mol Ther, 2009, 17, (9), 1643-1650.
133. Mann, R.; Mulligan, R.C.; Baltimore, D., Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell, 1983, 33, (1), 153-159.
134. Naldini, L.; Blomer, U.; Gage, F.H.; Trono, D.; Verma, I.M., Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A, 1996, 93, (21), 11382-11388.
135. Cline, M.J., Perspectives for gene therapy: inserting new genetic information into mammalian cells by physical techniques and viral vectors. Pharmacology & therapeutics, 1985, 29, (1), 69-92.
136. Stocking, C.; Loliger, C.; Kawai, M.; Suciu, S.; Gough, N.; Ostertag, W., Identification of genes involved in growth autonomy of hematopoietic cells by analysis of factor-independent mutants. Cell, 1988, 53, (6), 869-879.
137. Cavazzana-Calvo, M.; Hacein-Bey, S.; de Saint Basile, G.; Gross, F.; Yvon, E.; Nusbaum, P.; Selz, F.; Hue, C.; Certain, S.; Casanova, J.L.; Bousso, P.; Deist, F.L.; Fischer, A., Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science, 2000, 288, (5466), 669-672.
138. Gaspar, H.B.; Parsley, K.L.; Howe, S.; King, D.; Gilmour, K.C.; Sinclair, J.; Brouns, G.; Schmidt, M.; Von Kalle, C.; Barington, T.; Jakobsen, M.A.; Christensen, H.O.; Al Ghonaium, A.; White, H.N.; Smith, J.L.; Levinsky, R.J.; Ali, R.R.; Kinnon, C.; Thrasher, A.J., Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet, 2004, 364, (9452), 2181-2187.
139. Kustikova, O.S.; Schiedlmeier, B.; Brugman, M.H.; Stahlhut, M.; Bartels, S.; Li, Z.; Baum, C., Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. Mol Ther, 2009, 17, (9), 1537-1547.
140. Woods, N.B.; Muessig, A.; Schmidt, M.; Flygare, J.; Olsson, K.; Salmon, P.; Trono, D.; von Kalle, C.; Karlsson, S., Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis. Blood, 2003, 101, (4), 1284-1289.
141. Wang, G.P.; Levine, B.L.; Binder, G.K.; Berry, C.C.; Malani, N.; McGarrity, G.; Tebas, P.; June, C.H.; Bushman, F.D., Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol Ther, 2009, 17, (5), 844-850.
142. Zhou, S.; Mody, D.; DeRavin, S.S.; Hauer, J.; Lu, T.; Ma, Z.; Hacein-Bey Abina, S.; Gray, J.T.; Greene, M.R.; Cavazzana-Calvo, M.; Malech, H.L.; Sorrentino, B.P., A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells. Blood, 2010, 116, (6), 900-908.
143. Cavazzana-Calvo, M.; Payen, E.; Negre, O.; Wang, G.; Hehir, K.; Fusil, F.; Down, J.; Denaro, M.; Brady, T.; Westerman, K.; Cavallesco, R.; Gillet-Legrand, B.; Caccavelli, L.; Sgarra, R.; Maouche-Chretien, L.; Bernaudin, F.; Girot, R.; Dorazio, R.; Mulder, G.J.; Polack, A.; Bank, A.; Soulier, J.; Larghero, J.; Kabbara, N.; Dalle, B.; Gourmel, B.; Socie, G.; Chretien, S.; Cartier, N.; Aubourg, P.; Fischer, A.; Cornetta, K.; Galacteros, F.; Beuzard, Y.; Gluckman, E.; Bushman, F.; Hacein-Bey-Abina, S.; Leboulch, P., Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature, 2010, 467, (7313), 318-322.
144. Prasad, S.; Ravindran, J.; Aggarwal, B.B., NF-kappaB and cancer: how intimate is this relationship. Molecular and cellular biochemistry, 2010, 336, (1-2), 25-37.
145. Yang, L.; Bailey, L.; Baltimore, D.; Wang, P., Targeting lentiviral vectors to specific cell types in vivo. Proc Natl Acad Sci U S A, 2006, 103, (31), 11479-11484.
146. He, Y.; Zhang, J.; Mi, Z.; Robbins, P.; Falo, L.D., Jr., Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol, 2005, 174, (6), 3808-3817.
147. Goold, H.D.; Escors, D.; Conlan, T.J.; Chakraverty, R.; Bennett, C.L., Conventional DC are required for the activation of helperdependent CD8 T cell responses after cutaneous vaccination with lentiviral vectors J. Immunol., 2011, 186, (8), 4565-4572.
148. Racaniello, V.R.; Baltimore, D., Cloned poliovirus complementary DNA is infectious in mammalian cells. Science, 1981, 214, (4523), 916-919.
149. Racaniello, V.R.; Baltimore, D., Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. Proc Natl Acad Sci U S A, 1981, 78, (8), 4887-4891.
150. Liljestrom, P.; Lusa, S.; Huylebroeck, D.; Garoff, H., In vitro mutagenesis of a full-length cDNA clone of Semliki Forest virus: the small 6,000-molecular-weight membrane protein modulates virus release. J Virol, 1991, 65, (8), 4107-4113.
151. Enjuanes, L.; Sola, I.; Alonso, S.; Escors, D.; Zuniga, S., Coronavirus reverse genetics and development of vectors for gene expression. Curr Top Microbiol Immunol, 2005, 287, 161-197.
152. Escors, D.; Izeta, A.; Capiscol, C.; Enjuanes, L., Transmissible gastroenteritis coronavirus packaging signal is located at the 5' end of the virus genome. J Virol, 2003, 77, (14), 7890-7902.
153. Almazan, F.; Gonzalez, J.M.; Penzes, Z.; Izeta, A.; Calvo, E.; Plana-Duran, J.; Enjuanes, L., Engineering the largest RNA virus genome as an infectious bacterial artificial chromosome. Proc Natl Acad Sci U S A, 2000, 97, (10), 5516-5521.
154. Almazan, F.; Dediego, M.L.; Galan, C.; Escors, D.; Alvarez, E.; Ortego, J.; Sola, I.; Zuniga, S.; Alonso, S.; Moreno, J.L.; Nogales, A.; Capiscol, C.; Enjuanes, L., Construction of a severe acute respiratory syndrome coronavirus infectious cDNA clone and a replicon to study coronavirus RNA synthesis. J Virol, 2006, 80, (21), 10900-10906.
155. Hoffmann, E.; Neumann, G.; Kawaoka, Y.; Hobom, G.; Webster, R.G., A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A, 2000, 97, (11), 6108-6113.
156. Neumann, G.; Watanabe, T.; Ito, H.; Watanabe, S.; Goto, H.; Gao, P.; Hughes, M.; Perez, D.R.; Donis, R.; Hoffmann, E.; Hobom, G.; Kawaoka, Y., Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A, 1999, 96, (16), 9345-9350.
157. Kochan, G.; Escors, D.; Gonzalez, J.M.; Casasnovas, J.M.; Esteban, M., Membrane cell fusion activity of the vaccinia virus A17-A27 protein complex. Cell Microbiol, 2008, 10, (1), 149-164.
158. Gomez, C.E.; Najera, J.L.; Krupa, M.; Perdiguero, B.; Esteban, M., MVA and NYVAC as Vaccines Against Emergent Infectious Diseases and Cancer. Curr Gene Ther, 2011.
159. Flynn, B.J.; Kastenmuller, K.; Wille-Reece, U.; Tomaras, G.D.; Alam, M.; Lindsay, R.W.; Salazar, A.M.; Perdiguero, B.; Gomez, C.E.; Wagner, R.; Esteban, M.; Park, C.G.; Trumpfheller, C.; Keler, T.; Pantaleo, G.; Steinman, R.M.; Seder, R., Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A, 2011, 108, (17), 7131-7136.
160. Delaloye, J.; Roger, T.; Steiner-Tardivel, Q.G.; Le Roy, D.; Knaup Reymond, M.; Akira, S.; Petrilli, V.; Gomez, C.E.; Perdiguero, B.; Tschopp, J.; Pantaleo, G.; Esteban, M.; Calandra, T., Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS pathogens, 2009, 5, (6), e1000480.
161. Perez-Jimenez, E.; Kochan, G.; Gherardi, M.M.; Esteban, M., MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis. Microbes Infect, 2006, 8, (3), 810-822.
162. Cornu, T.I.; Cathomen, T., Targeted genome modifications using integrase-deficient lentiviral vectors. Mol Ther, 2007, 15, (12), 2107-2113.
163. Brown, B.D.; Venneri, M.A.; Zingale, A.; Sergi Sergi, L.; Naldini, L., Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med, 2006, 12, (5), 585-591.
164. Lombardo, A.; Genovese, P.; Beausejour, C.M.; Colleoni, S.; Lee, Y.L.; Kim, K.A.; Ando, D.; Urnov, F.D.; Galli, C.; Gregory, P.D.; Holmes, M.C.; Naldini, L., Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol, 2007, 25, (11), 1298-1306.